Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | ||||
0.00 | -1.11M | -1.31M | -566.00K | -21.00K |
EBIT | ||||
-76.24M | -68.86M | -51.20M | -36.83M | -20.68M |
EBITDA | ||||
-76.24M | -64.98M | -38.21M | -31.17M | -31.95M |
Net Income Common Stockholders | ||||
0.00 | -64.47M | -24.17M | -23.98M | -31.67M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
71.64M | 86.89M | 38.25M | 84.70M | 19.84M |
Total Assets | ||||
79.90M | 94.89M | 48.36M | 93.65M | 23.36M |
Total Debt | ||||
1.81M | 2.79M | 3.65M | 2.88M | 1.62M |
Net Debt | ||||
-69.82M | -84.10M | -34.60M | -81.82M | -18.21M |
Total Liabilities | ||||
18.23M | 16.45M | 12.37M | 24.14M | 58.49M |
Stockholders Equity | ||||
61.67M | 78.44M | 35.99M | 69.52M | -35.13M |
Cash Flow | Free Cash Flow | |||
-63.15M | -52.33M | -46.43M | -36.11M | -18.27M |
Operating Cash Flow | ||||
-62.60M | -52.07M | -45.86M | -33.68M | -18.27M |
Investing Cash Flow | ||||
-532.00K | -267.00K | -576.00K | -2.43M | 198.34K |
Financing Cash Flow | ||||
47.88M | 100.97M | 55.00K | 100.97M | 11.29M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $5.35B | 3.83 | -41.61% | 2.85% | 17.10% | 1.22% | |
40 Underperform | $116.14M | ― | -62.38% | ― | 178.84% | -40.60% | |
39 Underperform | $68.00M | ― | -59.64% | ― | ― | -40.59% | |
39 Underperform | $68.55M | ― | -46.28% | ― | -33.00% | 54.91% | |
36 Underperform | $77.77M | ― | -130.38% | ― | 134.56% | 61.91% | |
35 Underperform | $81.27M | ― | -101.73% | ― | ― | 21.40% |
On March 19, 2025, Jasper Therapeutics entered into a Sales Agreement with Jefferies LLC to potentially sell up to $100 million in common stock, providing flexibility in capital raising. The company also terminated its previous sales agreement with Cantor Fitzgerald & Co. on March 14, 2025, without incurring material penalties, having not sold any shares under that agreement.